Successfully results from clinical study with Vacc-4x and Endocine

Oslo 10.05.2012 – Successful Immunization and Safety Documented in Nasal Administration Study of the HIV Vaccine Vacc-4x together with Endocine This New Option May Offer Easier Treatment Access for HIV Patients Globally News Summary * Vaccine related immune responses found in HIV patients given Vacc-4x together with Endocine through nasal administration in a placebo controlled …

Read more

HIV treatment with nasal-drop form

Oslo 10.04.2012 – Bionor Pharma ASA (OSE: BIONOR) today announces that the placebo controlled study of nasally administered HIV therapeutic vaccine Vacc-4x in combination with Eurocine Vaccines` Endocine has been finalized in Q1 as planned and previously communicated. 24 patients were included, and 23 completed the study. No serious adverse events have been reported. Analysis …

Read more

Clinical status for Vacc-4x and Revlimid®

BioCentury Publications, Inc., a leading provider of value-added information on strategic issues in life science, has in their report BioCentury Week in Review Aug 29, 2011, published the clinical status of the upcoming clinical trial regarding Bionor’s therapeutic vaccine, Vacc-4x in combination with Revlimid®. Link to the reprint